EVOTEC SE (EVT.DE) Fundamental Analysis & Valuation

FRA:EVT • DE0005664809

5.464 EUR
-0.19 (-3.33%)
Last: Mar 5, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This EVT.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EVT. EVT was compared to 18 industry peers in the Life Sciences Tools & Services industry. While EVT seems to be doing ok healthwise, there are quite some concerns on its profitability. EVT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. EVT.DE Profitability Analysis

1.1 Basic Checks

  • EVT had negative earnings in the past year.
  • EVT had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: EVT reported negative net income in multiple years.
  • In the past 5 years EVT always reported a positive cash flow from operatings.
EVT.DE Yearly Net Income VS EBIT VS OCF VS FCFEVT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • The Return On Assets of EVT (-8.97%) is worse than 88.89% of its industry peers.
  • With a Return On Equity value of -19.87%, EVT is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVT.DE Yearly ROA, ROE, ROICEVT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • With a Gross Margin value of 10.82%, EVT is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
  • EVT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for EVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVT.DE Yearly Profit, Operating, Gross MarginsEVT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. EVT.DE Health Analysis

2.1 Basic Checks

  • EVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EVT has more shares outstanding
  • EVT has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for EVT has been reduced compared to a year ago.
EVT.DE Yearly Shares OutstandingEVT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EVT.DE Yearly Total Debt VS Total AssetsEVT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • EVT has an Altman-Z score of 1.14. This is a bad value and indicates that EVT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of EVT (1.14) is worse than 72.22% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that EVT is not too dependend on debt financing.
  • EVT has a Debt to Equity ratio of 0.48. This is in the better half of the industry: EVT outperforms 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z 1.14
ROIC/WACCN/A
WACC7.73%
EVT.DE Yearly LT Debt VS Equity VS FCFEVT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • EVT has a Current Ratio of 2.12. This indicates that EVT is financially healthy and has no problem in meeting its short term obligations.
  • EVT has a Current ratio of 2.12. This is amongst the best in the industry. EVT outperforms 88.89% of its industry peers.
  • A Quick Ratio of 2.03 indicates that EVT has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.03, EVT belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 2.03
EVT.DE Yearly Current Assets VS Current LiabilitesEVT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. EVT.DE Growth Analysis

3.1 Past

  • The earnings per share for EVT have decreased strongly by -136.17% in the last year.
  • The Revenue has decreased by -2.67% in the past year.
  • Measured over the past years, EVT shows a quite strong growth in Revenue. The Revenue has been growing by 12.29% on average per year.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.36% on average over the next years. This is quite good.
  • EVT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.91% yearly.
EPS Next Y50.73%
EPS Next 2Y35.51%
EPS Next 3Y27.78%
EPS Next 5Y18.36%
Revenue Next Year-2.87%
Revenue Next 2Y2.01%
Revenue Next 3Y4.83%
Revenue Next 5Y4.91%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EVT.DE Yearly Revenue VS EstimatesEVT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
EVT.DE Yearly EPS VS EstimatesEVT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. EVT.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EVT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVT.DE Price Earnings VS Forward Price EarningsEVT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 -30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EVT is valued expensively inside the industry as 83.33% of the companies are valued cheaper.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1179.72
EVT.DE Per share dataEVT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EVT's earnings are expected to grow with 27.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.51%
EPS Next 3Y27.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EVT.DE Dividend Analysis

5.1 Amount

  • EVT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EVT.DE Fundamentals: All Metrics, Ratios and Statistics

EVOTEC SE

FRA:EVT (3/5/2026, 7:00:00 PM)

5.464

-0.19 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05
Earnings (Next)N/A
Inst Owners50.94%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.94B
Revenue(TTM)756.33M
Net Income(TTM)-158.98M
Analysts78.46
Price Target9.07 (66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.59%
Min EPS beat(2)-21.86%
Max EPS beat(2)-3.31%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.97%
Min Revenue beat(2)-9.17%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.99%
Min Revenue beat(4)-9.17%
Max Revenue beat(4)-0.93%
Revenue beat(8)1
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)1.12%
Revenue beat(16)7
Avg Revenue beat(16)2.95%
PT rev (1m)2.56%
PT rev (3m)-1.76%
EPS NQ rev (1m)47.37%
EPS NQ rev (3m)47.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.34%
Revenue NQ rev (1m)1.79%
Revenue NQ rev (3m)1.79%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.57
P/FCF N/A
P/OCF 1376.1
P/B 2.42
P/tB 3.88
EV/EBITDA 1179.72
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0
OCFY0.07%
SpS2.13
BVpS2.25
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.82%
FCFM N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA 209.82
Cap/Depr 90.72%
Cap/Sales 12.19%
Interest Coverage N/A
Cash Conversion 76.3%
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 2.03
Altman-Z 1.14
F-Score4
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y50.73%
EPS Next 2Y35.51%
EPS Next 3Y27.78%
EPS Next 5Y18.36%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
Revenue Next Year-2.87%
Revenue Next 2Y2.01%
Revenue Next 3Y4.83%
Revenue Next 5Y4.91%
EBIT growth 1Y-6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.95%
EBIT Next 3Y47.8%
EBIT Next 5Y32.84%
FCF growth 1Y52.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y107.69%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%

EVOTEC SE / EVT.DE FAQ

Can you provide the ChartMill fundamental rating for EVOTEC SE?

ChartMill assigns a fundamental rating of 3 / 10 to EVT.DE.


What is the valuation status for EVT stock?

ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE (EVT.DE). This can be considered as Overvalued.


How profitable is EVOTEC SE (EVT.DE) stock?

EVOTEC SE (EVT.DE) has a profitability rating of 1 / 10.


What is the financial health of EVOTEC SE (EVT.DE) stock?

The financial health rating of EVOTEC SE (EVT.DE) is 5 / 10.


Can you provide the expected EPS growth for EVT stock?

The Earnings per Share (EPS) of EVOTEC SE (EVT.DE) is expected to grow by 50.73% in the next year.